CDKN2A and breast carcinoma: Examining the frequency of CNAs in 32 known breast cancer copy number driver genes in the whole TNBC cohort, the BL1 subtype presents the highest number of CNAs with high gain/amplification levels involving CDKN2A/B (FDR = 5.6 × 10−5 and 7.5 × 10−5) genes than other subtypes, providing the basis for future genomic-driven targeted therapies [61].